Vancomycin is a glycopeptide antibiotic medication used to treat certain bacterial infections.[4] It is administered intravenously (injection into a vein) to treat complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant Staphylococcus aureus.[5] Blood levels may be measured to determine the correct dose. Vancomycin is also taken orally (by mouth) to treat Clostridioides difficile infections.[4][6][7] When taken orally, it is poorly absorbed.[4]
Vancomycin
WorldBrand briefing
AI supplementOriginal synthesis to sit alongside the encyclopedia article below. Not part of Wikipedia; verify facts on Wikipedia when precision matters.
Vancomycin is a first-generation glycopeptide antibiotic derived from soil actinomycete cultures, widely regarded as a critical last-line therapeutic for severe, drug-resistant Gram-positive bacterial infections that do not respond to other common antibiotic classes. It has no cross-resistance with most unrelated antimicrobial families, and is a mainstay of care for hospital-acquired superbug infections globally.
Key moments
- 1956Discovered by researchers at Eli Lilly from a Streptomyces orientalis soil sample collected in Borneo, initially tested as a treatment for untreatable penicillin-resistant staph infections in surgical patients
- 1958Received formal US Food and Drug Administration approval for clinical systemic use
- 1961Methicillin-resistant Staphylococcus aureus (MRSA) first identified in the UK, creating immediate, widespread clinical demand for vancomycin as one of the only effective treatments for the new multidrug-resistant superbug
- 1980s–1990sLarge-scale adoption in hospital settings worldwide, with improved purification processes increasing drug purity above 95% and drastically reducing historical high rates of ototoxicity and nephrotoxicity
- 2002First documented case of vancomycin-resistant Staphylococcus aureus (VRSA) in the United States, prompting formal global antimicrobial stewardship guidelines to restrict unnecessary vancomycin prescription
Unique Mechanism of Action Drives Long-Term Clinical Utility
Unlike beta-lactam antibiotics that target penicillin-binding proteins to disrupt cell wall synthesis, vancomycin binds directly to the D-alanine-D-alanine terminal structure of bacterial cell wall precursor molecules, blocking cell wall assembly completely. This distinct mechanism means resistance cannot develop via the common beta-lactamase mutation pathways that disable most penicillin and cephalosporin drugs, allowing vancomycin to retain efficacy against nearly all Gram-positive pathogens for nearly 70 years after its launch.
Targeted Administration Rules Reduce Unnecessary Overuse
Vancomycin has extremely low oral bioavailability, so standard oral formulations are not absorbed into the bloodstream at all, and are only approved to treat gastrointestinal Clostridioides difficile infections. All systemic treatment for skin, bone, heart, blood or central nervous system Gram-positive infections requires slow intravenous infusion, which reduces casual, inappropriate outpatient use of the drug far more effectively than many widely overprescribed oral antibiotics.
Global Stewardship Efforts Face Ongoing Resistance Risks
The slow spread of vancomycin-resistant enterococci (VRE) and rare VRSA cases across global health systems creates a major public health vulnerability, as very few alternative affordable, accessible treatments exist for immunocompromised patients with systemic infections caused by these strains. Most major hospital systems now require formal prior authorization from infectious disease specialists before vancomycin can be prescribed, to preserve the drug's long-term effectiveness as a last-resort therapeutic.